This study is testing a new medicine called Lunsekimig for adults with moderate-to-severe asthma. The study will compare different doses of Lunsekimig to a placebo, which is a treatment with no active medicine. People joining the study must be between 18 and 80 years old and have asthma that was diagnosed by a doctor at least 12 months ago. They should already be taking certain asthma medicines and have had at least one asthma attack in the past year.
Important terms: ICS stands for "inhaled corticosteroids," a common asthma treatment. ACQ-5 is a test that measures asthma control; a score over 1.5 means asthma isn't well controlled.
- Length: This is a Phase 2b study, which means it is testing safety and how well the treatment works.
- Visits: Participants will need to visit a study center multiple times.
- Risks: People with other lung diseases, serious infections, or who smoke may not qualify.
It's important to talk to your doctor if you are interested in joining this study.
How understandable was the trial content above?
Hard to understand
Easy to understand